Introduction. The present study evaluated the effects of benazepril, an angiotensin-converting enzyme inhibitor on haemodynamic, biochemical, and immunohistochemical (Bax and Bcl-2 protein) indices in ischaemia and reperfusion (IR) injury. Materials and methods. Male Wistar albino rats were divided into three groups and were orally administered saline once daily (IR-sham and IR-control) or benazepril (30 mg/kg/day; IR-benazepril) for 14 days. On the 15 th day, in the IR-control and IR-benazepril groups, rats were subjected to left anterior descending coronary artery occlusion for 45 minutes followed by a one-hour reperfusion. Haemodynamic parameters were recorded and rats were sacrificed; hearts were isolated for biochemical estimation and immunohistochemistry.
Introduction
Myocardial infarction (MI) is initiated by occlusion or blockade of a major coronary artery. Ischaemia, due to coronary artery occlusion, leads to a series of complex cellular events that results in myocardial cell death. 1 Restoration of blood flow to the ischaemic myocardium during the early phase of MI is the only way to save the myocardium from eventual necrosis. However, reperfusion of ischaemic tissue is known to be accompanied by more myocardial damage. 2 Furthermore, apoptosis, a programmed cell death, is regulated by a number of proteins, such as the Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic). 3 Its stimulus during myocardial ischaemia-reperfusion (IR) insult/injury might also contribute to cell loss. [4] [5] [6] [7] The progressive loss of cardiomyocytes by apoptosis in a heart that is already compromised poses an additional workload on the remaining viable myocytes that may be unsupportable, leading to further deterioration of cardiac function and resulting in further activation of pathological death signal pathways. 8, 9 Inhibition of the apoptotic process has been reported to prevent or slow down the loss of contractile cells, and thus was suggested as an additional therapeutic approach in cardiac diseases. 10 It has been reported that these programmed cell death pathways can be inhibited by angiotensin-converting enzyme (ACE) inhibitors, antioxidants, and other anti-apoptotic agents. 11, 12 ACE inhibitors are widely used for the treatment of a number of cardiovascular diseases including hypertension, congestive heart failure, acute MI, and diabetic nephropathy. They improve the quality of life and decrease the mortality and morbidity of patients with MI and heart failure. 13 Many studies have reported the benefits of ACE inhibitors in relation to infarct size reduction, attenuation of ventricular remodelling, and decreased incidence of reperfusion-induced arrhythmia. [14] [15] [16] These effects have been ascribed to both blockade of angiotensin II synthesis and a decrease in bradykinin breakdown, which stimulates the production of nitric oxide and prostaglandins. 17 Benazepril, an ACE inhibitor, has been reported to markedly reduced infarct size and significantly attenuate heart hypertrophy in chronic MI in rats. 18 Additionally, benazepril treatment is also known to reduce diabetes-induced oxidative stress and apoptosis, which may contribute to its efficacy in reducing diabetic complications. 19 However, only a few studies are presently available that document its cardioprotective potential correlated to its effects on haemodynamic variables, apoptosis, cardiac injury marker enzymes, and lipid peroxidation. Therefore, with this in mind, it would be interesting and possibly fruitful to study the cardioprotective effects of benazepril in an IR model of MI. The present investigation was planned to characterise the effects of benazepril on cardiac functions, lipid peroxidation, and cardiac injury markers. In addition, in order to achieve an insight into the underlying mechanisms of its cardioprotective effect in cardiac IR injury, immunohistochemical localisation of Bax and Bcl-2 proteins was performed to identify the drug's role in apoptosis.
Materials and methods

Animals
The study protocol was reviewed and approved by the Institutional Animal Ethics Committee (IAEC No-299/2005), and conformed to the Indian National Science Academy (INSA) Guidelines for the use and care of experimental animals in research. Male Wistar rats weighing 150-250 g were obtained from the Central Animal House Facility of All India Institute of Medical Sciences, New Delhi, India. The rats were maintained under standard laboratory conditions at 25±2 o C, relative humidity 60±15% and natural light-dark photo period. Commercial pellet diet (Ashirwad Industries Ltd., Chandigarh, India) and tap water were provided ad libitum. The commercial pellet diet contained 24% protein, 5% fat, 4% fibre, 55% carbohydrate, 0.6% calcium, 0.3% phosphorous, 10% moisture, and 9% ash w/w.
Chemicals
Benazepril was a generous gift from Torrent Pharmaceuticals Ltd., Ahmedabad, Gujarat, India. All chemicals were of analytical grade, purchased from Sigma Chemical Co., St. Louis, USA. The ABC staining kit and primary (Bax mouse monoclonal IgG 2b and Bcl-2 mouse monoclonal IgG I ) and secondary antibodies (anti-mouse IgG) were procured from Santa Cruz Biotechnology, USA. Double distilled water was used in all biochemical assays and molecular techniques.
Experimental protocol
The animals were randomly divided into three main groups.
Group 1: IR-sham group
Rats were administered 0.9% saline orally (2 ml/ kg) using intragastric tubes for 14 days and then sacrificed on the 15 th day. The animals were subjected to the entire surgical procedure and thread was passed beneath the coronary artery, but the left anterior descending (LAD) coronary artery was not ligated. The number of animals studied in this group was eight.
Group 2: IR-control group
In this group, rats were administered 0.9% saline orally (2 ml/kg) using intragastric tubes for 14 days; thereafter, on the 15 th day, the experimental animals were subjected to a 45-minute LAD coronary artery ligation followed by a one-hour reperfusion-induced myocardial injury. The number of animals studied in this group was 12.
Group 3: IR-benazepril group
Benazepril (30 mg/kg/day) was dissolved in saline and was administered orally (15 mg/ml), using intragastric tubes, to animals for 14 days. On the 15 th day, the rats were subjected to a protocol of a 45-minute LAD coronary artery ligation and a one-hour reperfusion. The number of animals studied in this group was 12.
Experimental procedure
Surgical procedure for LAD coronary artery occlusion and reperfusion
The detailed surgical procedure for LAD coronary artery occlusion-reperfusion and recording of haemodynamic parameters have been described in our previous studies. 1, 20 Briefly, rats of all the experimental groups were anaesthetised with pentobarbitone sodium (60 mg/kg, i.p.). Atropine was co-administered with the anaesthetic to reduce broncho-tracheal secretions. Body temperature was monitored and maintained at 37 o C throughout the experimental protocol. The neck was opened with a ventral midline incision, and a tracheostomy was performed and the rats were ventilated with room air from a positive pressure ventilator (Inco, India) using compressed air at the rate of 70 strokes per minute and a tidal volume of 10 ml/ kg. The left jugular vein was cannulated with a polyethylene tube for continuous infusion of 0.9% saline. After that, the right carotid artery was cannulated and the cannula filled with heparinised saline was connected to the cardiac output monitor CARDIOSYS CO-101 (Experimetria, Hungary) Paper SAGE Publications 2009 Los Angeles, London, New Delhi and Singapore via a pressure transducer for measurement of mean arterial pressure (MAP). A left thoracotomy was performed at the fifth intercostal space and the pericardium was opened to expose the heart. The LAD coronary artery was ligated 4-5 mm from its origin by a 5-0 silk suture with an atraumatic needle, and ends of this ligature were passed through a small vinyl tube to form a snare. After completion of the surgical procedure, the heart was returned to its normal position in the thorax. The thoracic cavity was covered with saline-soaked gauze to prevent the heart from drying. The animals were then allowed to stabilise for 15 minutes before LAD coronary artery ligation. Myocardial ischaemia was induced by one stage occlusion of the LAD coronary artery by pressing the polyethylene tubing against the ventricular wall and then fixing it in place by clamping the vinyl tube with a haemostat (except in IR-sham rats). A wide bore (1.5 mm) sterile metal cannula was inserted into the cavity of the left ventricle from the posterior apical region of the heart. The cannula was connected to a pressure transducer (Gold Statham P23ID, USA) and the whole system was filled with heparinised saline (heparin 50 units/ml). Left ventricular systolic and left ventricular end-diastolic pressure (LVEDP) were measured on a multichannel polygraph (Grass 7D, USA) from the left ventricular pressures curve at lower and higher sensitivity of the preamplifier, respectively. The maximum rates of rise and fall of left ventricular pressure (peak +LVdP/dt and peak -LVdP/dt) were measured by the electronic differentiator from the signal output of the channel recording left ventricular pressure. A bolus of heparin (30 IU) was administered immediately before coronary artery occlusion for prophylaxis against thrombus formation around the snare. The animals then underwent 45 minutes of ischaemia, confirmed visually in situ by the appearance of regional epicardial cyanosis. The myocardium was reperfused by releasing the snare gently for a one-hour period. Successful reperfusion was confirmed by visualisation of arterial blood flow through the artery and appearance of hyperaemia over the surface of the previously ischaemic cyanotic segment. At the end of the reperfusion period, animals were sacrificed using an overdose of pentobarbitone sodium (100 mg/kg, i.v.) and the heart was removed for biochemical and immunohistochemical studies. For biochemical estimations, hearts were stored in liquid nitrogen, whereas for immunohistochemistry, hearts were fixed in 10% buffer formalin.
Biochemical studies
The hearts were removed from liquid nitrogen, weighed and a 10% homogenate was prepared in ice-chilled phosphate buffer (50 mM, pH 7.4 ). An aliquot of the homogenate was used for the estimation of thiobarbituric acid reactive substances (TBARS) according to the method described by Okhawa et al. 21 The rest of the homogenate was then centrifuged at 5,000 rpm for 20 minutes at 4 o C and the supernatant was used for the estimation of lactate dehydrogenase (LDH) by the method of Cabaud and Wroblewski. 22 
Determination of myocardial apoptosis
Immunostaining for the localisation of Bax and Bcl-2 proteins Indirect immunoperoxidase staining was performed as described with some modifications. 23 Briefly, tissue sections (4-µm thickness) mounted on poly-L-lysine-coated glass slides were deparaffinised with xylene. After washing in graded concentrations of ethanol, the specimens were incubated with methanol containing 2% H 2 O 2 to inhibit endogenous peroxidase activity. The slides were then washed with PBS for five minutes. The sections were incubated with blocking buffer (10% normal goat serum) for 10 minutes at room temperature. Next, the slides were incubated overnight at 4 o C with primary mouse Bax and Bcl-2 monoclonal antibody (1:500). For the negative control, the primary antibody was omitted. After washing with PBS, tissue sections were incubated for one hour with biotinylated goat secondary antibodies (anti-mouse IgG, 1:100). Subsequently, sections were washed and incubated for 30 minutes with peroxidase-conjugated streptavidin-biotin complex. The target protein (Bax/Bcl-2) was visualised by incubation in peroxidase substrate (H 2 O 2 ) using 3,3'-diaminobenzidine as the chromogen and the sections were counterstained with haematoxylin.
Statistical analysis
All numerical data in figures are expressed as the mean±SD. Two-way analysis of variance (ANOVA) was applied for statistical analysis with post hoc analysis (Bonferroni multiple range test) and a p value < 0.05 was considered as statistically significant. The statistical analysis was carried out by version 15 of the SPSS programmer software. Figure 1 shows the time course change of MAP in vehicle-and drug-treated rats. In the IR-control group, a continuous and significant fall in MAP was observed after coronary artery ligation and throughout the reperfusion period compared to the IR-sham group (p<0.05). Fourteen days' Figures 5 and 6 show the activities of LDH and TBARS levels in the hearts of vehicle-and drugtreated rats. A significant decrease in LDH activity (p<0.01) and an increase in TBARS level (p<0.001) were observed in the IR-control group as compared to the IR-sham group. Benazepril pretreatment markedly reduced lipid peroxidation, as TBARS levels were significantly reduced (from 80.81±9.05 to 67.37±6.76 nmol/g tissue, p<0.05) in comparison to the IR-control group. Also, a marked restoration in myocardial enzyme LDH (from 60.53±5.43 to 68.92±3.62 units/mg protein, p<0.05) was observed in the benazepril-treated group as compared to the IR-control group. 
Results
Effect of benazepril on haemodynamic variables in experimentally-induced MI
Effect of benazepril on myocardial injury markers and lipid peroxidation in experimentally-induced MI
Effect of benazepril on expression of Bcl-2 and Bax proteins in experimentallyinduced MI
To determine whether the cardioprotection by benazepril was accompanied by a change in the apoptosis regulatory proteins (Bax, Bcl-2), immunohistopathological studies were conducted. These proteins were distributed in the cytoplasm of cardiomyocytes. Figures 7 and 8 show their expression in the ischaemic region of ventricle myocardium after ischaemia and reperfusion. In the non-ischaemic left ventricular region, slightly positive Bax and Bcl-2 immunoreactivities were observed (figures 7A and 8A). There was almost no difference in Bcl-2 staining between drugtreated and IR-control groups (figures 7B and 7C). 
Discussion
The results of the present study demonstrate the cardioprotective effect of benazepril in an IR-induced model of MI in rats. Benazepril exhibited its cardioprotective effects by improving cardiac functionalities (improved haemodynamic profile, restored ventricular functions), preserving myocardial LDH activity, and reducing formation of lipid peroxides. Furthermore, benazepril pretreatment increased the expression of Bcl-2 protein, which is anti-apoptotic, and reduced the expression of Bax protein, which is pro-apoptotic, in rat myocardium, thus preventing the process of apoptosis and loss of viable myocytes during IR challenge.
Myocardial ischaemia initiated by occlusion or blockade of a major coronary artery leads to a complex series of cellular events that can result in myocardial cell death. Prompt reperfusion of ischaemic myocardium relieves or at least greatly reduces ischaemia, and thus decreases the extent of morbidity and mortality associated with the precipitating acute MI. 24 It has been well documented that early reperfusion of viable but ischaemic myocardium (functionally jeopardised) is essential to prevent cardiac damage. However, reperfusion itself has been shown to enhance myocardial injury and leads to further complications such as diminished cardiac contractile function and metabolic derangements. Myocardial injury associated with restoration of blood flow into previously ischaemic tissue has been termed 'reperfusion injury'. Reperfusion injury is defined as 'those metabolic, functional and structural consequences of restoring coronary artery flow that can be avoided or reversed by modification of the condition of reperfusion'. 25 In the present study, we observed that following IR challenge, there was marked arterial and ventricular dysfunction (viz. increased LVEDP and reduced ±LVdP/dt). These observations are in accordance with earlier reported studies with similar experimental set-ups. 1, 20, 26 Pretreatment with benazepril significantly improved MAP and left ventricular functions in IR-challenged rats. Benazepril pretreatment not only decreased LVEDP (marker of pre-load), but also increased +LVdP/dt (inotropic effect) and -LVdP/dt (lusitropic effect), and thus prevented the deleterious ventricular effects produced by IR challenge. Earlier work on effects of ACE inhibitors in different models of experimental MI has reported similar cardioprotective effects. 16, [27] [28] [29] [30] Among these studies, Hartman 30 attributed the cardioprotective effects of ACE inhibition to bradykinin and nitric oxide involvement, which was further demonstrated by abolition of cardioprotection when animals were pretreated with the bradykinin antagonist, HOE 140, and nitric oxide synthesis was inhibited with NG-nitro-L-arginine methylester. Other clinical and experimental studies have also reported that the beneficial effects of ACE inhibitors were mediated by a bradykinin-nitric oxide pathway. [31] [32] [33] This was so, because ACE inhibitors not only inhibit angiotensin II generation but also prevent degradation of bradykinin. One recent study reported that kallikrein gene delivery reduced MI and apoptosis in ischaemia-reperfusion injury via bradykinin. 34 In addition, delayed preconditioning and reduction of arrhythmias 16 by ACE inhibitor pretreatment 35 during IR challenge have been reported to improve left ventricular function. Therefore, the observed cardioprotective effects of this study can be attributed to benazepril actions on the bradykinin pathway, preconditioning, and arrhythmias.
Development of oxidative stress due to sudden bursts in the generation of oxygen free radicals (OFR) immediately after restitution of blood flow to a previously ischaemic myocardium is well known. 36, 37 Free radicals are difficult to estimate directly because of their high reactivity and short half-life. They are known to react with various biological components such as lipids of cellular membranes to form oxidised products. 38 Estimation of these oxidised products in a tissue can provide information about the production of OFR in that system as well as the extent of injury inflicted to the cell. 39, 40 Therefore, the level of a stable product of lipid peroxidation, malondialdehyde, was used to measure OFR generation in our study. In the present study, an elevated level of malondialdehyde in the IR-control group indicates increased oxidative stress due to IR challenge, as compared to the IR-sham group. Benazepril treatment on the other hand demonstrated a decreased level of lipid peroxide formation, thus indicating attenuation of the OFR generation process during IR insult.
Apart from lipid peroxidation, alterations in levels of myocardium-specific LDH have been considered as an important marker of myocardial injury. 41, 42 We observed a significant fall in myocardial LDH activity in the IR-control group as compared to the IR-sham group; the fall in the level of LDH might be due to the leaking out of this enzyme from the pores of the cell membrane formed due to lipid peroxidation by OFR. The observation that benazepril treatment significantly restored LDH activity compared to the IR-control demonstrates its myocardial salvaging effects.
In reperfused ischaemic hearts, an increase in oxidative stress and a decrease in antioxidant defence have been reported to lead to cardiac dysfunction. This failure of cardiac function depends upon various pathological changes in the biochemistry and structural integrity of myocardium. Among these changes, loss of myocytes due to apoptosis plays an important role. 8, [43] [44] [45] [46] Apoptosis being programmed cell death involves many regulatory proteins and signalling molecules to bring about its accomplishment. Among such regulatory proteins, a group of proteins belonging to the Bcl-2 family of proteins is an important stakeholder as it regulates the universal effectors of apoptosis, i.e. caspases. The Bcl-2 family of proteins includes Bcl-2, Bcl-xL proteins, which are anti-apoptotic in nature, and Bax, Bad, which are pro-apoptotic in their functioning. 47, 48 Apoptosis, being dependent on the expression of these regulatory proteins, can be prevented by modulation of these proteins. 49, 50 Using the technique of immunohistochemistry, we observed the modulation in expression of Bcl-2/Bax proteins in all the groups. Benazepril treatment upregulated the expression of the anti-apoptotic protein, Bcl-2, and downregulated the expression of the pro-apoptotic protein, Bax. This upregulation of Bcl-2 might have resulted in formation of heterodimers with Bax, resulting in no/less free Bax protein available for homodimerisation. It is well known that if Bax homodimerises predominantly, cell death will occur, but when Bcl-2 and Bax heterodimerisation prevails, cells can survive. 8 These effects of benazepril of modulating the expression of Bax and Bcl-2 proteins in favour of anti-apoptosis could have led to salvaging of cardiomyocytes destined for apoptosis due to IR injury. Availability of more viable cells with improved functionality along with an improved antioxidant defence system stimulated by benazepril treatment in IR challenge thus provides strong evidence in support of its cardioprotective potential.
Overall, the findings of the present study strongly indicate the cardioprotective effects of benazepril in our IR injury model of MI. However, in order to elucidate other mechanisms which might be involved in cardioprotection offered by benazepril treatment and to advocate the potential clinical implications of its therapy, further detailed investigations are required to establish the therapeutic potential of ACE inhibition, in particular benazepril treatment, in ischaemic heart disease.
Conclusion
To conclude, our findings suggest that benazepril pretreatment attenuated myocardial injury and functional impairment in ischaemic reperfused hearts. Moreover, our results show that an ACE inhibitor, benazepril, preserved myocardium by increasing the Bcl-2/Bax ratio during ischaemiareperfusion, and thereby making the cardiomyocytes more resistant to the apoptotic mode of cell death. This finding has important clinical implications in the therapeutic use of benazepril and probably other ACE inhibitors in ischaemic heart disease as a cardioprotective agent. 
